MichaelJamesBaineMDPhD
Radiation Oncology • Omaha, NEUrologic Cancer
Associate Professor and Medical Director
Dr. Baine is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
505 S 45th St
Omaha, NE 68198Phone+1 402-559-5600
Summary
- I am a member of the Department of Radiation Oncology at the University of Nebraska Medical Center, acting in a physician scientist role. My clinical practice is focused on GU malignancies with my lab investigating pancreas, prostate, and bladder cancers. I have specific interests in radiomics, ultrahypofractionated radiation treatment for prostate, body SBRT for oligometastatic diseases, and the interactions between high dose-per-fraction radiation treatments and the immune system with the hope of leveraging this into greater efficacy of immunotherapy.
Education & Training
University of Nebraska Medical Center College of MedicineResidency, Radiation Oncology, 2015 - 2019- University of Nebraska Medical Center College of MedicineInternship, Internal Medicine, 2014 - 2015
University of Nebraska College of Medicine
Certifications & Licensure
IA State Medical License 2019 - 2026
NE State Medical License 2019 - 2026- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Sigma Xi 2022
- Alpha Sigma Nu Loyola Marymount University, 2006
- Inductee Alpha Omega Alpha Honor Medical Society
Clinical Trials
- Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer Start of enrollment: 2016 Sep 16
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Start of enrollment: 2019 Jun 03
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Start of enrollment: 2020 Dec 15
- Join now to see all
Publications & Presentations
PubMed
- Heme Oxygenase-1 and Prostate Cancer: Function, Regulation, and Implication in Cancer Therapy.Ramia J Salloom, Iman M Ahmad, Dania Z Sahtout, Michael J Baine, Maher Y Abdalla
International Journal of Molecular Sciences. 2024-08-24 - 1 citationsExogenous APN protects normal tissues from radiation-induced oxidative damage and fibrosis in mice and prostate cancer patients with higher levels of APN have less rad...Joshua A McDowell, Elizabeth A Kosmacek, Michael J Baine, Oluwaseun Adebisi, Cheng Zheng
Redox Biology. 2024-07-01 - Predictive Value of Multiparametric Magnetic Resonance Imaging in Risk Group Stratification of Prostate Adenocarcinoma.Benjamin T Bonebrake, Elsa Parr, Linda My Huynh, Brendan Coutu, Neil Hansen
Advances in Radiation Oncology. 2024-06-01
Press Mentions
- The Impact of Neoadjuvant and Adjuvant Immunotherapy on the Survival of Pancreatic Cancer Patients: A Retrospective AnalysisJune 9th, 2020
The Impact of Immunotherapy on the Survival of Pancreatic Adenocarcinoma Patients Who Received Definitive Surgery of the Pancreatic Tumor: A Retrospective Analysis of the National Cancer DatabaseJune 3rd, 2020
Professional Memberships
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
